Prognostic features and outcomes in primary liver sarcoma.

150 Background: Primary liver sarcoma (PLS) is a rare and aggressive hepatic malignancy. Due to the low incidence of PLS, prognostic factors have not been well characterized. The purpose of our study was to evaluate survival outcomes in primary hepatic sarcomas and determine which factors predict survival. Methods: The Surveillance Epidemiology and End Results registry was used to identify patients with PLS from 1988-2009. Patients were evaluated by standard clinical and pathological indices including: age, gender, race, tumor size, tumor grade, histology, and extent of disease. Treatment related factors included surgery and radiation. Overall survival was assessed by Kaplan-Meier method. Univariate and stepwise multivariate Cox proportional hazards analyses were performed to identify prognostic factors. Results: 541 patients with PLS were identified. The mean age was 52 and most patients were male (55%) and white (75%). The most common histology type was blood vessel tumors (50.1%) followed by soft tissue neoplasms (17.7%) and complex mixed-stromal neoplasms (14.6%). Only 33% of patients underwent surgery and most (93%) did not receive radiation. When assessing outcomes, we observed median overall survival (OS) and cancer specific survival (CSS) of 6 months for the entire cohort. When stratified by treatment type, those who received surgery + radiation had the best survival (MS=97mos, p<.001) compared to those who received either radiation alone (MS=5mos) or no treatment (MS=2mos). Stepwise multivariate analysis showed that age, male gender, tumor size, advanced stage, and no surgery were independent predictors of worse survival, all p-values < .005. Conclusions: Primary liver sarcoma is an aggressive hepatic malignancy with low median OS of 6 months. Patients treated with surgery + radiation had the best outcome with a median survival of 97 months. Independent predictors for decreased survival included age, gender, tumor size, advanced stage, and no surgery.

Download Full-text

Nomograms Predict Overall Survival and Cancer-Speciﬁc Survival in Patients with Fibrosarcoma: A SEER-Based Study

Journal of Oncology ◽

10.1155/2020/8284931 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Guang-Heng Xiang ◽

Juan-Juan Zhu ◽

Chen-Rong Ke ◽

Yi-Min Weng ◽

Ming-Qiao Fang ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Tumor Size ◽

Multivariate Analyses ◽

Discrimination Performance ◽

Tumor Stage ◽

Good Discrimination ◽

Cancer Specific Survival ◽

Internal Validation ◽

Clinical Benefits

Purpose. Due to the rarity, it is difficult to predict the survival of patients with fibrosarcoma. This study aimed to apply a nomogram to predict survival outcomes in patients with fibrosarcoma. Methods. A total of 2235 patients with diagnoses of fibrosarcoma were registered in the Surveillance, Epidemiology, and End Results database, of whom 663 patients were eventually enrolled. Univariate and multivariate Cox analyses were used to identify independent prognostic factors. Nomograms were constructed to predict 3-year and 5‐year overall survival and cancer‐specific survival of patients with fibrosarcoma. Results. In univariate and multivariate analyses of OS, age, sex, race, tumor stage, pathologic grade, use of surgery, and tumor size were identiﬁed as independent prognostic factors. Age, sex, tumor stage, pathologic grade, use of surgery, and tumor size were significantly associated with CSS. These characteristics were further included to establish the nomogram for predicting 3-year and 5-year OS and CSS. For the internal validation of the nomogram predictions of OS and CSS, the C-indices were 0.784 and 0.801. Conclusion. We developed the nomograms that estimated 3-year and 5-year OS and CSS. These nomograms not only have good discrimination performance and calibration but also provide patients with better clinical benefits.

Download Full-text

Nomograms Predict Overall Survival And Cancer-Speciﬁc Survival In Patients With Fibrosarcoma: A SEER-Based Study

10.21203/rs.3.rs-16360/v1 ◽

2020 ◽

Author(s):

Guangheng Xiang ◽

Juan-Juan Zhu ◽

Chen-Rong Ke ◽

Yi-Min Weng ◽

Ming-Qiao Fang ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Tumor Size ◽

Multivariate Analyses ◽

Discrimination Performance ◽

Tumor Stage ◽

Good Discrimination ◽

Cancer Specific Survival ◽

Internal Validation ◽

Clinical Benefits

Abstract Background Due to the rarity, it is difficult to predict the survival of patients with fibrosarcoma. This study aimed to apply a nomogram to predict survival outcomes in patients with fibrosarcoma. Methods A total of 2235 patients with diagnoses of fibrosarcoma were registered in the Surveillance, Epidemiology, and End Results database, of whom 663 patients were eventually enrolled. Univariate and multivariate Cox analyses were used to identify independent prognostic factors. Nomograms were constructed to predict 3‐ and 5‐year overall survival and cancer‐specific survival of patients with fibrosarcoma. Results In univariate and multivariate analyses of OS, age, sex, race, tumor stage, pathologic grade, use of surgery and tumor size identiﬁed as independent prognostic factors. Age, sex, tumor stage, pathologic grade, use of surgery and tumor size were significantly associated with CSS. These characteristics were further included to establish the nomogram for predicting 3- and 5- year OS and CSS. For the internal validation of the nomogram predictions of OS and CSS, the C-indices were 0.784 and 0.801. Conclusion We developed and validated the nomograms that estimated 3- and 5-year OS and CSS. These nomograms not only have good discrimination performance and calibration, but also provide patients with better clinical benefits.

Download Full-text

Chemotherapy Plus Radiotherapy Versus Radiotherapy in Patients With Small Cell Carcinoma of the Esophagus: A SEER Database Analysis

Cancer Control ◽

10.1177/1073274821989321 ◽

2021 ◽

Vol 28 ◽

pp. 107327482198932

Author(s):

Tao Li ◽

Sijia Chen ◽

Zongkai Zhang ◽

Limei Lin ◽

Qian Wu ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Tumor Size ◽

Small Cell ◽

Prognosis Factors ◽

Cancer Specific Survival ◽

Carcinoma Of The Esophagus ◽

Factors Affecting

Background: Small cell carcinoma of the esophagus is a rare malignant tumor. We aimed to explore the chemotherapeutic efficacy on the prognosis of patients with small cell carcinoma of the esophagus who received radiotherapy. Methods: To identify the population of interest, Surveillance, Epidemiology, and End Results data from 1996 to 2016 were chosen. Univariate and multivariate analyses were used to probe into prognosis factors. Multivariate Cox regression analysis was conducted to identify factors related to overall survival and cancer-specific survival. Results: Overall, data from 162 patients were analyzed in this study. Tumor size (P = 0.014), T staging (P = 0.028), and chemotherapy (P < 0.001) were independent prognostic factors affecting overall survival. Patients with regional disease (hazard ratio = 5.435, P < 0.001) and distant metastasis (hazard ratio = 2.183, P < 0.001) who received radiotherapy alone had worse survival than those receiving chemoradiotherapy. Tumor size (P = 0.004) and chemotherapy (P < 0.001) were independent prognostic factors affecting cancer-specific survival. Tumor size was an independent factor affecting cancer-specific survival for patients receiving chemoradiation. Conclusions: Age, T staging, tumor size, primary site, and chemotherapy are independent prognosis factors affecting overall survival and cancer-specific survival in patients with small cell carcinoma of the esophagus who receive radiotherapy. Chemotherapy might further improve cancer-specific survival in patients with small cell carcinoma of the esophagus receiving radiotherapy at all stages.

Download Full-text

Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

BMC Cancer ◽

10.1186/s12885-021-07800-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Jieqiong Wen ◽

Wanbin Chen ◽

Yayun Zhu ◽

Pengbo Zhang

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Tumor Size ◽

Proportional Hazards Model ◽

Tumor Location ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Multivariable Analyses ◽

End Results

Abstract Background Glioblastoma (GBM) is a highly malignant brain tumor with poor survival and prognosis. Randomized trials have demonstrated that chemotherapy improves survival in patients with GBM. This study aims to examine the clinical characteristics that are potentially associated with the efficacy of chemotherapy and the risk factors of GBM. Methods A total of 25,698 patients diagnosed with GBM were identified between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER). The clinical and demographic variables between groups were examined by Student’s t-test and Pearson’s chi-square test. GBM-specific survival (GBMSS) and overall survival (OS) were evaluated using the Kaplan-Meier method with the log-rank test. Univariable and multivariable analyses were also performed using the Cox proportional hazards model to identify statistically significant prognostic factors. Results Patients who received chemotherapy had better overall survival (median OS 13 vs. Three months, HR = 1.9224, 95%CI 1.8571–1.9900, p < 0.0001) and better GBMSS (median GBMSS of 12 vs. Three months, HR = 1.9379, 95%CI 1.8632–2.0156, p < 0.0001), compared to patients who did not. Further subgroup analysis revealed that among patients who underwent chemotherapy, those who were younger, with a supratentorial tumor, received surgery, or radiotherapy had both improved OS and GBMSS. Age, race, tumor location, tumor size, and treatments were identified as independent prognostic factors by multivariable analyses for patients with glioblastoma. Conclusion Patients with GBM who were younger (< 65 years), underwent surgery, or radiotherapy can benefit more from chemotherapeutic regimens. Age, race, tumor size, tumor location, surgery, radiotherapy, and chemotherapy were factors associated with the prognosis of patients with GBM.

Download Full-text

Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma

Scientific Reports ◽

10.1038/s41598-021-86786-y ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Min Wang ◽

Bo Yuan ◽

Zhen-huan Zhou ◽

Wei-wei Han

Keyword(s):

Prognostic Factors ◽

Tumor Size ◽

Survival Rates ◽

Tumor Grade ◽

Figo Stage ◽

Cervical Adenocarcinoma ◽

Stage Ii ◽

Prognostic Indicators ◽

Rank Test ◽

Cancer Specific Survival

AbstractWe aimed to assess the clinicopathological features and to determine the prognostic factors of cervical adenocarcinoma (AC). Relevant data were extracted from surveillance, epidemiology and end results database from 2004 to 2015. The log-rank test and Cox proportional hazard analysis were subsequently utilized to identify independent prognostic factors. A total of 3102 patients were identified. The enrolled patients were characterized by higher proportion of early FIGO stage (stage I: 65.9%; stage II: 14.1%), low pathological grade (grade I/II: 49.1%) and tumor size ≤ 4 cm (46.8%). The 5- and 10-year cancer-specific survival rates of these patients were 74.47% and 70.00%, respectively. Meanwhile, the 5- and 10-year overall survival (OS) rates were 71.52% and 65.17%, respectively. Multivariate analysis revealed that married status, surgery as well as chemotherapy were independent favorable prognostic indicators. Additionally, aged > 45, tumor grade III/IV, tumor size > 4 cm, advanced FIGO stage and pelvic lymph node metastasis (LNM) were unfavorable prognostic factors (all P < 0.01). Stratified analysis found that patients without surgery could significantly benefit from chemotherapy and radiotherapy. In addition, chemotherapy could significantly improve the survival in stage II–IV patients and radiotherapy could only improve the survival in stage III patients (all P < 0.01). Marital status, age, grade, tumor size, FIGO stage, surgery, pelvic LNM and chemotherapy were significantly associated with the prognosis of cervical AC.

Download Full-text

Association of low RKIP expression with poor prognosis in non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.3068 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 3068-3068

Author(s):

Lingbin Meng ◽

Rui Ji ◽

Damian A. Laber ◽

Xuebo Yan ◽

Xiaochun Xu

Keyword(s):

Overall Survival ◽

Tumor Size ◽

Proportional Hazards ◽

Cox Proportional Hazards ◽

Tnm Stage ◽

Erk Signaling ◽

Small Cell Lung ◽

Proportional Hazards Regression ◽

Kaplan Meier ◽

Nsclc Patients

3068 Background: Raf1 kinase inhibitor protein (RKIP) is able to bind Raf1 to inhibit Ras-Raf-MEK-ERK signaling, a major oncogenic pathway. It has been reported that reduced RKIP expression associates with poor prognosis in many cancers, including gastric adenocarcinoma, gliomas and bladder cancer. However, there are only several studies on its role in non-small cell lung cancer (NSCLC) and the conclusion is still controversial. Hence, we performed this study to assess the prognostic significance of RKIP in our NSCLC population. Methods: Between June 2017 and June 2020, 156 NSCLC patients treated at our hospital were included for the present study. None of the patients had received chemotherapy, radiotherapy or surgery before. Their tumor tissues and surrounding normal lung tissues were collected for immunostain and western blot analysis of RKIP expression and ERK signaling. We collected information about gender, age, histological differentiation, tumor size, TNM stage, and lymph node status. Survival curves were analyzed using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic value of various variables in a univariate and multivariate setting. Results: Immunostain and western blot results showed a lower RKIP expression and a higher p-ERK level in cancer tissues compared with the surrounding normal tissues. A reduced RKIP expression with high level of p-ERK was also observed in TNM stages III and IV as compared with I and II. Pearson's chi-squared test confirmed low RKIP expression associated with poorer TNM stage ( p< 0.001) and N-stage ( p< 0.05). No significant correlation was observed between RKIP expression level and gender, age, histological type or tumor size. Kaplan-Meier survival analysis revealed that patients with low RKIP expression had significantly worse overall survival than patients with high RKIP expression ( p= 0.019, log-rank). This conclusion was consistent in the stage I&II patients ( p= 0.011, log-rank) but not in the stage III&IV patients ( p= 0.711, log-rank). Univariate Cox proportional hazards regression analysis indicated Tumor size, TNM stage and RKIP expression significantly affected overall survival of the NSCLC patients. Multivariate Cox proportional hazards regression analysis confirmed RKIP expression remained a significant predictor of survival after correcting for the effects of Tumor size and TNM stage (hazard ratio = 1.730, 95% confidence interval = 1.017 – 2.942, p = 0.043). Conclusions: In this study, low RKIP expression was a poor prognostic indicator in NSCLC as it significantly correlated with poorer TNM stage, N-status, and overall survival. Our findings suggest that by inhibiting Ras-Raf-MEK-ERK pathway RKIP may play an anti-tumor role in NSCLC.

Download Full-text

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

Journal of Clinical Oncology ◽

10.1200/jco.1991.9.2.211 ◽

1991 ◽

Vol 9 (2) ◽

pp. 211-219 ◽

Cited By ~ 156

Author(s):

B Coiffier ◽

C Gisselbrecht ◽

J M Vose ◽

H Tilly ◽

R Herbrecht ◽

...

Keyword(s):

Bone Marrow ◽

Overall Survival ◽

Prognostic Factors ◽

Serum Albumin ◽

Serum Albumin Level ◽

Bone Marrow Involvement ◽

Prognostic Index ◽

Albumin Level ◽

Advanced Stage ◽

Low Serum

The objectives of this study were to determine prognostic factors for response to treatment, freedom-from-relapse (FFR) survival, and overall survival of 737 aggressive malignant lymphoma patients treated with the doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, methotrexate with leucovorin, ifosfamide, etoposide, asparaginase, and cytarabine (LNH-84) regimen; to construct a prognostic index with factors isolated by multivariate analyses; and to validate this prognostic index with another set of patients. Complete response (CR) was reached in 75% of LNH-84 patients, and 30% of them relapsed. With a median follow-up of 36 months, median FFR survival and median overall survival were not reached. Low serum albumin level, high tumoral mass, weight loss, bone marrow involvement, greater than or equal to 2 extranodal sites, and increased lactic dehydrogenase (LDH) level were associated with a low response rate. Advanced stage, increased LDH level, and nonlarge-cell histologic subtypes (diffuse mixed, lymphoblastic, and small non-cleaved) were statistically associated with a high relapse rate and short FFR survival. Increased LDH level, low serum albumin level, tumoral mass larger than 10 cm, greater than or equal to 2 extranodal sites, advanced stage, and age older than 65 years were statistically associated with short overall survival. Four of these parameters, namely, LDH level, stage, number of extranodal sites, and tumoral mass, were put together to construct a prognostic index. This index partitioned LNH-84 patients into three subgroups of good, intermediate, and poor prognosis (P less than .00001): CR rates of 93%, 83%, and 61%; relapse rates of 12%, 25%, and 45%; 3-year FFR survival of 87%, 73%, and 53%, and 3-year survival of 88%, 71%, and 41%, respectively. This prognostic index was applied to a test set of patients: 155 patients treated on protocols of the Nebraska Lymphoma Study Group. Using this index, these patients had 3-year FFR survival of 70%, 40%, and 22% (P = .0002) and 3-year survival of 79%, 52%, and 31% (P = .005). In patients with aggressive lymphomas, this simple prognostic index could distinguish between patients requiring intensive treatment such as autologous bone marrow transplantation in first complete remission and those who could be treated with standard regimens.

Download Full-text

Nomogram for predicting the overall survival and cancer-specific survival of patients with extremity liposarcoma: a population-based study

BMC Cancer ◽

10.1186/s12885-020-07396-x ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Lin Ye ◽

Chuan Hu ◽

Cailin Wang ◽

Weiyang Yu ◽

Feijun Liu ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Area Under The Curve ◽

Risk Groups ◽

Population Based ◽

Cancer Specific Survival ◽

Kaplan Meier ◽

Extremity Soft Tissue Sarcoma ◽

Individual Survival ◽

Size Grade

Abstract Background Extremity liposarcoma represents 25% of extremity soft tissue sarcoma and has a better prognosis than liposarcoma occurring in other anatomic sites. The purpose of this study was to develop two nomograms for predicting the overall survival (OS) and cancer-specific survival (CSS) of patients with extremity liposarcoma. Methods A total of 2170 patients diagnosed with primary extremity liposarcoma between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox analyses were performed to explore the independent prognostic factors and establish two nomograms. The area under the curve (AUC), C-index, calibration curve, decision curve analysis (DCA), Kaplan-Meier analysis, and subgroup analyses were used to evaluate the nomograms. Results Six variables were identified as independent prognostic factors for both OS and CSS. In the training cohort, the AUCs of the OS nomogram were 0.842, 0.841, and 0.823 for predicting 3-, 5-, and 8-year OS, respectively, while the AUCs of the CSS nomogram were 0.889, 0.884, and 0.859 for predicting 3-, 5-, and 8-year CSS, respectively. Calibration plots and DCA revealed that the nomogram had a satisfactory ability to predict OS and CSS. The above results were also observed in the validation cohort. In addition, the C-indices of both nomograms were significantly higher than those of all independent prognostic factors in both the training and validation cohorts. Stratification of the patients into high- and low-risk groups highlighted the differences in prognosis between the two groups in the training and validation cohorts. Conclusion Age, sex, tumor size, grade, M stage, and surgery status were confirmed as independent prognostic variables for both OS and CSS in extremity liposarcoma patients. Two nomograms based on the above variables were established to provide more accurate individual survival predictions for extremity liposarcoma patients and to help physicians make appropriate clinical decisions.

Download Full-text

Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study

Sarcoma ◽

10.1155/2020/2437850 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Jules Lansu ◽

Winan J. Van Houdt ◽

Michael Schaapveld ◽

Iris Walraven ◽

Michiel A. J. Van de Sande ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

The Netherlands ◽

Metastatic Disease ◽

Lower Limb ◽

Tumor Size ◽

Tumor Location ◽

Population Based ◽

Population Based Study ◽

Over Time

Background. The purpose of this study was to evaluate the overall survival (OS) and associated characteristics for patients with Myxoid Liposarcoma (MLS) over time in The Netherlands. Methods. A population-based study was performed of patients with primary localized (n = 851) and metastatic (n = 50) MLS diagnosed in The Netherlands between 1989 and 2016, based on data from the National Cancer Registry. Results. The median age of the MLS patients was 49 years, and approximately two-thirds was located in the lower limb. An association was revealed between age and the risk of having a Round Cell (RC) tumor. OS rates for primary localized MLS were 93%, 83%, 78%, and 66% after 1, 3, 5, and 10 years, respectively. The median OS for patients with metastatic disease at diagnosis was 10 months. Increasing age (Hazard Ratio (HR) 1.05, p=0.00), a tumor size >5 cm (HR 2.18; p=0.00), and tumor location (trunk HR 1.29; p=0.09, upper limb HR 0.83; p=0.55, and “other” locations HR 2.73; p=0.00, as compared to lower limb) were independent prognostic factors for OS. The percentage of patients treated with radiotherapy (RT) increased over time, and preoperative RT gradually replaced postoperative RT. In contrast to patients with localized disease, significant improvement of OS was observed in patients with metastatic disease over time. Conclusions. In this large nationwide cohort, tumor size and tumor location were independent prognostic factors for OS. Furthermore, a higher probability of an RC tumor with increasing age was suggested. An increased use of RT over the years did not translate into improved OS for localized MLS.

Download Full-text

Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era

Blood ◽

10.1182/blood.v120.21.1980.1980 ◽

2012 ◽

Vol 120 (21) ◽

pp. 1980-1980

Author(s):

Sarah Welch ◽

Philippe Armand ◽

Haesook T Kim ◽

Ann S. LaCasce ◽

Eric Jacobsen ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factors ◽

Risk Group ◽

Prognostic Score ◽

B Cell Lymphoma ◽

Advanced Stage ◽

Prognostic Assessment ◽

Large B Cell Lymphoma ◽

Symptomatic Relapse ◽

Prognostic Importance

Abstract Abstract 1980 High dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL) who are chemosensitive to salvage therapy. There is now evidence that the achievement of complete remission by PET scan (PET-CR) after salvage therapy is a favorable determinant of ASCT outcome, implying that PET response should be part of the prognostic assessment for patients considering ASCT. However, it is unclear whether other prognostic factors are still relevant in patients getting post-salvage PET scanning. Moreover, while ASCT is often also used for patients with R/R transformed indolent lymphoma (TIL), there are no data on whether prognostic factors that are important for DLBCL patients, especially PET response to salvage, are similarly prognostic in this population. We studied 163 consecutive adult patients who underwent ASCT at 2 institutions over the last decade for R/R DLBCL (122 patients) or R/R TIL (41 patients) and had a post-salvage PET scan. 98% were chemosensitive after salvage by conventional criteria. Among the 122 patients with DLBCL, 52 (43%) remained PET positive after salvage. PET-positivity was more likely for patients with advanced stage at relapse, and for those whose first remission duration was less than 6 months. After a median follow-up of 49 months from ASCT, the 4-year overall survival (OS) for PET-positive patients was 54% versus 74% for PET-negative patients (p=0.016), while the corresponding 4-year progression-free survival (PFS) was 30% versus 63% (p<0.0001). In multivariable models, the following were adverse prognostic factors for OS and PFS: PET positivity after salvage, age ≥60 years, CNS involvement at relapse, symptomatic relapse, and advanced stage at relapse (for OS only). Based on those factors, we constructed a prognostic score, assigning 1 point for each of the above factors (except for CNS relapse which was assigned 3 points). Patients in the low-risk group (0–1 points) had a 4y OS of 90% and 4y PFS of 74%, compared to 63% and 45% for patients in the intermediate-risk group (2–3 points), and 19% and 0% for patients in the high-risk group (4+ points) (p<0.0001 for both OS and PFS differences) (Figure 1A). The post-ASCT outcome of patients with TIL was not significantly different from that of DLBCL patients (4y OS 53% versus 69%, p=0.23, and 4y PFS 44% versus 54%, p=0.4). Notably, in this group, PET status after salvage had no prognostic relevance (Figure 1B). In fact, in multivariable models for OS and PFS, only short duration of 1st remission and elevated LDH at relapse (for OS only) were significant. Figure. Overall Survival after ASCT. A. DLBCL cohort, stratified by prognostic score; B. TIL cohort, stratified by post-salvage PET. Figure. Overall Survival after ASCT. A. DLBCL cohort, stratified by prognostic score; B. TIL cohort, stratified by post-salvage PET. This study confirms the prognostic importance of post-salvage PET remission status. However, If PET response is included in the prognostic assessment, traditional risk factors such as receipt of 1st line rituximab, short duration of 1st remission, or elevated second-line aaIPI appear to lose their prognostic importance. Instead, we identified 4 other clinical factors that were strongly associated with outcome: advanced age, CNS relapse, advanced stage at relapse, and symptomatic relapse. Our prognostic score is simple to calculate and stratifies patients into 3 groups with significantly different OS and PFS. An important potential use of this score, if further validated, could be to identify a high-risk population whose outcomes after ASCT are dismal (0% PFS and 19% OS at 4 years), and who should be considered for alternative treatment approaches. Moreover, our results suggest that prognostic factors for patients with TIL may be entirely different; in particular, PET response to salvage may not be prognostically important. This is important to consider when designing clinical trials or interpreting their results in this patient population. Disclosures: No relevant conflicts of interest to declare.

Download Full-text